Strongbridge Biopharma (NASDAQ:SBBP) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Strongbridge Biopharma (NASDAQ:SBBP) in a report published on Thursday, January 18th. HC Wainwright currently has a $18.00 price target on the biotechnology company’s stock.

Other equities analysts also recently issued research reports about the company. BidaskClub upgraded Strongbridge Biopharma from a buy rating to a strong-buy rating in a report on Thursday, January 11th. Zacks Investment Research downgraded Strongbridge Biopharma from a buy rating to a hold rating in a report on Wednesday, January 17th. Cantor Fitzgerald set a $14.00 price objective on Strongbridge Biopharma and gave the stock a buy rating in a report on Wednesday, January 17th. Finally, ValuEngine downgraded Strongbridge Biopharma from a hold rating to a sell rating in a report on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The company has an average rating of Hold and a consensus price target of $12.81.

Shares of Strongbridge Biopharma (NASDAQ SBBP) traded up $0.15 during mid-day trading on Thursday, reaching $6.80. The company had a trading volume of 207,805 shares, compared to its average volume of 349,230. The company has a debt-to-equity ratio of -1.89, a current ratio of 4.70 and a quick ratio of 4.61. The stock has a market capitalization of $265.04, a price-to-earnings ratio of -1.94 and a beta of 1.98. Strongbridge Biopharma has a 12 month low of $2.10 and a 12 month high of $9.02.

Strongbridge Biopharma (NASDAQ:SBBP) last posted its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.07. research analysts predict that Strongbridge Biopharma will post -2.86 EPS for the current year.

Large investors have recently modified their holdings of the company. Rhumbline Advisers bought a new position in shares of Strongbridge Biopharma during the second quarter valued at $154,000. California State Teachers Retirement System bought a new position in shares of Strongbridge Biopharma during the second quarter valued at $277,000. Teachers Advisors LLC bought a new position in shares of Strongbridge Biopharma during the second quarter valued at $297,000. Wells Fargo & Company MN increased its holdings in shares of Strongbridge Biopharma by 1,130.4% during the fourth quarter. Wells Fargo & Company MN now owns 44,640 shares of the biotechnology company’s stock valued at $324,000 after acquiring an additional 41,012 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of Strongbridge Biopharma during the second quarter valued at $331,000. Hedge funds and other institutional investors own 57.01% of the company’s stock.

WARNING: “Strongbridge Biopharma (NASDAQ:SBBP) Given “Buy” Rating at HC Wainwright” was originally published by Week Herald and is the property of of Week Herald. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://weekherald.com/2018/02/13/strongbridge-biopharma-sbbp-receives-buy-rating-from-hc-wainwright.html.

About Strongbridge Biopharma

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply